Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC
NCT04140526Phase 2Active, not recruiting
- Sponsor
- OncoC4
- Start
- Sep 2020
- Primary completion
- Dec 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of gotistobart in non-small cell lung cancer (NSCLC), solid tumor, melanoma and 16 more (3 arms), sponsored by OncoC4. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximal Tolerable Dose at 21 days and 2 more. Started Sep 2020; status: active, not recruiting.
02
Drugs
gotistobart
03
Conditions
non-small cell lung cancer (NSCLC)solid tumormelanomahead and neck squamous cell carcinoma (HNSCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04140526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04140526.